Brokers Offer Predictions for OLMA FY2025 Earnings

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) – Investment analysts at Lifesci Capital issued their FY2025 earnings estimates for Olema Pharmaceuticals in a report released on Wednesday, November 13th. Lifesci Capital analyst S. Slutsky expects that the company will post earnings per share of ($2.12) for the year. The consensus estimate for Olema Pharmaceuticals’ current full-year earnings is ($2.32) per share.

OLMA has been the topic of a number of other research reports. Oppenheimer reiterated an “outperform” rating and set a $30.00 price target on shares of Olema Pharmaceuticals in a report on Wednesday, August 7th. HC Wainwright reiterated a “buy” rating and issued a $30.00 target price on shares of Olema Pharmaceuticals in a report on Wednesday. Finally, JPMorgan Chase & Co. decreased their price target on shares of Olema Pharmaceuticals from $33.00 to $31.00 and set an “overweight” rating for the company in a report on Thursday, August 8th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $27.00.

Olema Pharmaceuticals Stock Down 9.2 %

Shares of NASDAQ:OLMA opened at $9.17 on Friday. The company’s fifty day moving average is $12.00 and its two-hundred day moving average is $11.96. The company has a market cap of $525.42 million, a P/E ratio of -4.19 and a beta of 2.02. Olema Pharmaceuticals has a 12-month low of $8.51 and a 12-month high of $17.10.

Olema Pharmaceuticals (NASDAQ:OLMA) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.60) EPS for the quarter, missing the consensus estimate of ($0.59) by ($0.01).

Hedge Funds Weigh In On Olema Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in the company. Conway Capital Management Inc. bought a new stake in Olema Pharmaceuticals in the third quarter worth approximately $119,000. Barclays PLC lifted its stake in shares of Olema Pharmaceuticals by 105.0% in the 3rd quarter. Barclays PLC now owns 94,915 shares of the company’s stock valued at $1,133,000 after purchasing an additional 48,614 shares during the last quarter. XTX Topco Ltd boosted its holdings in Olema Pharmaceuticals by 103.4% in the third quarter. XTX Topco Ltd now owns 25,332 shares of the company’s stock worth $302,000 after purchasing an additional 12,878 shares in the last quarter. EP Wealth Advisors LLC increased its position in Olema Pharmaceuticals by 5.2% during the third quarter. EP Wealth Advisors LLC now owns 48,655 shares of the company’s stock worth $581,000 after buying an additional 2,407 shares during the last quarter. Finally, Wellington Management Group LLP raised its holdings in Olema Pharmaceuticals by 10.8% during the third quarter. Wellington Management Group LLP now owns 1,002,685 shares of the company’s stock valued at $11,972,000 after buying an additional 97,428 shares in the last quarter. Institutional investors and hedge funds own 91.78% of the company’s stock.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.